单剂次HPV疫苗保护作用及接种策略的机遇和挑战

张梦; 吴丹; 梁晓峰

doi:10.11847/zgggws1139851

单剂次HPV疫苗保护作用及接种策略的机遇和挑战

doi: 10.11847/zgggws1139851

张梦^{1, 2},
吴丹²,
梁晓峰^{1, 3, ,}

1.
山西医科大学公共卫生学院，山西太原 030001
2.
中国疾病预防控制中心免疫规划中心
3.
暨南大学基础医学与公共卫生学院

基金项目: 中国疾病预防控制中心公共卫生应急反应机制的运行（131031001000200001）

详细信息

作者简介:
张梦（1997 – ），女，陕西咸阳人，硕士在读，研究方向：流行病与卫生统计学

通讯作者:
梁晓峰，E-mail：liangxf@jnu.edu.cn

中图分类号: R 186
计量
- 文章访问数: 68
- HTML全文浏览量: 12
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2022-07-25
- 网络出版日期: 2023-01-10

Protection efficiency and vaccination strategy of single-dose HPV vaccine: opportunity and challenges

ZHANG Meng^{1, 2},
WU Dan²,
LIANG Xiao-feng^{1, 3
, ,}

1.
School of Public Health, Shanxi Medical University, Taiyuan, Shanxi Province 030001, China

摘要

摘要: 接种人类乳头瘤病毒（human papilloma virus, HPV）疫苗可预防HPV感染和HPV相关癌症。目前大多数国家采用2剂次HPV疫苗接种方案，但越来越多的研究发现接种单剂次HPV疫苗具有潜在的保护效果。鉴于宫颈癌的巨大全球疾病负担及因HPV疫苗供应紧张而造成国家或地区间的供应日益严重不平等现象，世界卫生组织免疫策略咨询专家组（Strategic Advisory Group of Experts on Immunization, SAGE）在2022年4月相关会议上表明，单剂次HPV疫苗与2剂次或3剂次疫苗接种方案的保护作用相当。本文就HPV疫苗接种现状和单剂次HPV疫苗保护作用的相关研究进行综述，并分析未来实施单剂HPV疫苗接种策略的机遇和挑战。
- 人类乳头瘤病毒疫苗 /
- 保护作用 /
- 接种策略 /
- 机遇 /
- 挑战
Abstract: Vaccination against human papilloma virus (HPV) prevents HPV infections and HPV - related cancers. Most countries currently use a two - dose HPV vaccination schedule, but a growing number of studies have found potential effectiveness of single - dose HPV vaccine, sparking a debate about the feasibility of switching from a two - dose regimen to a single - dose regimen in the global vaccine community. Given the large global disease burden of cervical cancer and inequality between countries and regions due to the tight HPV vaccine supply, World Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) stated that single - dose schedules provide comparable protection to the two - or three - dose schedules at a relevant meeting in April 2022. In this article, we review current status of HPV vaccination and researches on the single - dose HPV vaccine protection, and analyze the opportunity and challenges for single - dose HPV vaccination strategy in the future.
- human papilloma virus vaccine /
- protective effect /
- vaccination strategy /
- opportunity /
- challenge

HTML全文

表 1 单剂次HPV疫苗的保护效力

研究地点	研究对象	HPV疫苗	随访时间（月）	相关指标	保护效力
研究地点	研究对象	HPV疫苗	随访时间（月）	相关指标	VE（%）	95 % CI
肯尼亚^[23]	15～20岁女性	单剂次九价Gardasil®9	18	HPV16/18持续性感染率	97.5	81.7 ～ 99.7
		单剂次二价Cervarix®			97.5	81.6 ～ 99.7
坦桑尼亚^[24]	9～14岁女性	Cervarix®、Gardasil®9	24	HPV16/18 IgG抗体阳性率		— ^a
印度^[25]	10～18岁女性	单剂次四价Gardasil®	120	HPV16/18持续性感染率	95.4	85.0 ～ 99.9
		2剂次四价Gardasil®			93.1	77.3 ～ 99.8
		3剂次四价Gardasil®			93.3	77.5 ～ 99.7
哥斯达黎加^[26]	18～25岁女性	单剂次二价Cervarix®	135.6	HPV16/18持续性感染率	82.1	40.2 ～ 97.0
		2剂次二价Cervarix®			83.8	19.5 ～ 99.2
		3剂次二价Cervarix®			80.2	70.7 ～87.0
注：a 接种单剂次Cervarix®、Gardasil®9后，HPV16 IgG抗体阳性率不劣于2剂次和3剂次同种HPV疫苗。

下载: 导出CSV

参考文献(34)

[1]	International Agency for Research on Cancer. GLOBOCAN 2020[EB/OL]. (2022 – 04 – 18)[2022 – 04 – 18]. https://gco.iarc.fr/.
[2]	Toh ZQ, Russell FM, Garland SM, et al. Human papillomavirus vaccination after COVID - 19[J]. JNCI Cancer Spectrum, 2021, 5(2): pkab011. doi: 10.1093/jncics/pkab011
[3]	Shadab R, Lavery JV, McFadden SAM, et al. Key ethical considerations to guide the adjudication of a single - dose HPV vaccine schedule[J]. Human Vaccines and Immunotherapeutics, 2022, 18(1): 1917231. doi: 10.1080/21645515.2021.1917231
[4]	World Health Organization. Vaccination schedule for human papilloma virus[EB/OL]. (2022 – 04 – 01)[2022 – 05 – 06]. https://immunizationdata.who.int/pages/schedule-by-disease/hpv.html?TARGETPOP_GENERAL=ADULTS + GENERAL + FEMALE.
[5]	Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study[J]. The Lancet Oncology, 2016, 17(1): 67 – 77. doi: 10.1016/S1470-2045(15)00414-3
[6]	Toh ZQ, Russell FM, Reyburn R, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study[J]. Clinical Infectious Diseases, 2017, 64(7): 852 – 859.
[7]	Bandyopadhyay S, Pal M. Single dose nonavalent HPV vaccine – need of the hour[J]. Nepal Journal of Epidemiology, 2020, 10(2): 871 – 873. doi: 10.3126/nje.v10i2.28962
[8]	Batmunkh T, Dalmau MT, Munkhsaikhan ME, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immuno-genic and reduces HPV detection rates in young women in Mongolia, six years after vaccination[J]. Vaccine, 2020, 38(27): 4316 – 4324. doi: 10.1016/j.vaccine.2020.04.041
[9]	World Health Organization. SAGE April 2022 meeting highlights[EB/OL]. (2022 – 04 – 11)[2022 – 04 – 18]. https://www.who.int/news/item/11-04-2022-sage-april-2022-meeting-highlights.
[10]	World Health Organization. One-dose human papillomavirus (HPV) vaccine offers solid protection against cervical cancer[EB/OL]. (2022 – 04 – 11)[2022 – 04 – 18]. https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer.
[11]	World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2022: conclusions and recommendations[EB/OL]. (2022 – 06 – 17)[2022 – 07 – 23]. https://www.who.int/publications/i/item/who-wer9724-261-276.
[12]	World Health Organization. Human papillomavirus vaccines. WHO position paper[J]. Weekly Epidemiological Record, 2009, 84(15): 118 – 131.
[13]	World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014 – Recommendations[J]. Vaccine, 2015, 33(36): 4383 – 4384. doi: 10.1016/j.vaccine.2014.12.002
[14]	World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017- recommendations[J]. Vaccine, 2017, 35(43): 5753 – 5755. doi: 10.1016/j.vaccine.2017.05.069
[15]	World Health Organization. Meeting of the strategic advisory group of experts on immunization, October 2019: conclusions and recommendations[J]. Weekly Epidemiological Record, 2019, 94(47): 541 – 559.
[16]	Mphuru A, Li AJ, Kyesi F, et al. National introduction of human papillomavirus (HPV) vaccine in Tanzania: programmatic decision - making and implementation[J]. Vaccine, 2022, 40(S1): A2 – A9.
[17]	Stanley M, Dull P. HPV single - dose vaccination: impact potential, evidence base and further evaluation[J]. Vaccine, 2018, 36(32): 4759 – 4760. doi: 10.1016/j.vaccine.2018.02.076
[18]	Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices[J]. Morbidity and Mortality Weekly Report, 2019, 68(32): 698 – 702. doi: 10.15585/mmwr.mm6832a3
[19]	World Health Organization. Progress and challenges with achiev-ing universal immunization coverage[EB/OL]. (2020 – 07 – 14)[2022 – 05 – 04]. https://www.who.int/publications/m/item/progress-and-challenges-with-achievinguniversal-immunization-coverage.
[20]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209 – 249. doi: 10.3322/caac.21660
[21]	World Health Organization. Global strategy to accelerate the elimina-tion of cervical cancer as a public health problem[EB/OL]. (2020 – 11 – 17)[2022 – 04 – 27]. https://www.who.int/publications/i/item/9789240014107.
[22]	Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010 – 2019[J]. Preventive Medicine, 2021, 144: 106399. doi: 10.1016/j.ypmed.2020.106399
[23]	Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single - dose human papillomavirus vaccination among young African Women[J]. NEJM Evidence, 2022, 1(5): EVIDoa2100056.
[24]	Watson-Jones D, Changalucha J, Whitworth H, et al. Immuno-genicity and safety results comparing single dose human papillo-mavirus vaccine with two or three doses in Tanzanian girls – the DoRIS Randomised Trial[EB/OL]. (2022 – 03 – 11)[2022 – 05 – 10]. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4055429#.
[25]	Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study[J]. The Lancet Oncology, 2021, 22(11): 1518 – 1529. doi: 10.1016/S1470-2045(21)00453-8
[26]	Kreimer AR, Sampson JN, Porras C, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial[J]. Journal of the National Cancer Institute, 2020, 112(10): 1038 – 1046. doi: 10.1093/jnci/djaa011
[27]	Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United States, 2003 – 2014[J]. The Journal of Infectious Diseases, 2017, 216(5): 594 – 603. doi: 10.1093/infdis/jix244
[28]	Spinner C, Ding LL, Bernstein DI, et al. Human papillomavirus vaccine effectiveness and herd protection in Young Women[J]. Pediatrics, 2019, 143(2): e20181902. doi: 10.1542/peds.2018-1902
[29]	Kim JJ. Could 1 dose be less efficacious than 2 doses but still be a great public health intervention?[EB/OL]. (2019 – 09 – 06)[2022 – 05 – 09]. https://www.hpvworld.com/media/29/media_section/0/5/1605/kim.pdf.
[30]	Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low - income and lower - middle - income countries[J]. The Lancet, 2020, 395(10224): 591 – 603. doi: 10.1016/S0140-6736(20)30157-4
[31]	Our World in Data. Share of adolescent girls vaccinated against the human papillomavirus, 2020[EB/OL]. (2022 – 05 – 10)[2022 – 05 – 10]. https://ourworldindata.org/grapher/coverage-of-the-human-papillomavirus-vaccine?country=Africa ~ Asia ~ Europe + and + North + America ~ Latin + America + and + the + Caribbean ~ Oceania ~ OWID_WRL.
[32]	Prem K, Choi YH, Bénard É, et al. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis[EB/OL]. (2021 – 02 – 08)[2022 – 05 – 10]. https://www.medrxiv.org/content/10.1101/2021.02.08.21251186v1.
[33]	Burger EA, Campos NG, Sy S, et al. Health and economic benefits of single - dose HPV vaccination in a Gavi-eligible country[J]. Vaccine, 2018, 36(32): 4823 – 4829. doi: 10.1016/j.vaccine.2018.04.061
[34]	World Health Organization. Report of the meeting on HPV vaccine coverage and impact monitoring[EB/OL]. (2019 – 11 – 20)[2022 – 05 – 18]. https://www.who.int/publications/i/item/WHO_IVB_10.05.